MRG 201

Drug Profile

MRG 201

Alternative Names: MRG-201; promiR-29; Synthetic microRNA-29 Mimic; Synthetic miR-29 Mimic

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer miRagen Therapeutics; Yale University
  • Class MicroRNAs; Skin disorder therapies
  • Mechanism of Action MicroRNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Scleroderma
  • Preclinical Pulmonary fibrosis

Most Recent Events

  • 27 Apr 2017 Interim pharmacodynamics , pharmacokinetics data from a phase I trial in Pulmonary fibrosis released by miRagen Therapeutics
  • 31 Mar 2017 Interim adverse events and pharmacodynamics data from a phase I trial in Pulmonary fibrosis released by miRagen Therapeutics
  • 01 Nov 2015 Phase-I clinical trials in Scleroderma in Canada (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top